Baorui Announces Subsidiary Fund Lending Disclosure per Regulatory Requirements

1. Date of Fact: 115/07/02

2. The balance of funds lent by the publicly issued company and its subsidiaries to others exceeds 20% of the latest financial statement net value of the publicly issued company:

(1) Name of the company receiving fund lending: Bora Pharmaceutical Holdings, LLC (2) Relationship with the lending company: Indirectly 100% owned subsidiary of the company (lent by subsidiary Upsher-Smith Laboratories, LLC) (3) Fund lending limit (in thousand NTD): 14,176,296 (4) Fund lending balance as of the date of fact (in thousand NTD): 798,000 (5) Reason for fund lending as of the date of fact: To strengthen operational funds required for obtaining U.S. drug approvals and related rights

(1) Name of the company receiving fund lending: Bora Pharmaceuticals USA Inc. (2) Relationship with the lending company: Directly 100% owned subsidiary of the company (lent by subsidiary Bora Global Ltd.) (3) Fund lending limit (in thousand NTD): 3,939,565 (4) Fund lending balance as of the date of fact (in thousand NTD): 2,601,480 (5) Reason for fund lending as of the date of fact: To strengthen operational funds required for the acquisition of CDMO operating assets in Maryland

(1) Name of the company receiving fund lending: Bora Pharmaceuticals Inc. (2) Relationship with the lending company: Indirectly 100% owned subsidiary of the company (lent by subsidiary Bora Pharmaceuticals USA Inc.) (3) Fund lending limit (in thousand NTD): 27,110,314 (4) Fund lending balance as of the date of fact (in thousand NTD): 798,000 (5) Reason for fund lending as of the date of fact: To strengthen operational funds required for Bora Pharmaceuticals Inc. to expand its CDMO business

(1) Name of the company receiving fund lending: Upsher-Smith Laboratories, LLC (2) Relationship with the lending company: Indirectly 100% owned subsidiary of the company (lent by subsidiary TWi Pharmaceuticals USA, Inc.) (3) Fund lending limit (in thousand NTD): 2,464,916 (4) Fund lending balance as of the date of fact (in thousand NTD): 1,188,265 (5) Reason for fund lending as of the date of fact: To strengthen operational funds and reclassify overdue accounts receivable into other receivables

(1) Name of the company receiving fund lending: Bora Pharmaceuticals Injectables Inc. (2) Relationship with the lending company: Indirectly 100% owned subsidiary of the company (lent by subsidiary Bora Pharmaceuticals USA Inc.) (3) Fund lending limit (in thousand NTD): 27,110,314 (4) Fund lending balance as of the date of fact (in thousand NTD): 239,400 (5) Reason for fund lending as of the date of fact: To strengthen operational funds and repay borrowings

3. Total fund lending balance as of the date of fact (in thousand NTD): 5,625,145

4. Ratio of fund lending balance to the latest financial statement net value of the publicly issued company: 38.61%

5. Source of funds lent to others: Subsidiary's own funds

6. Other matters to be disclosed: None.